Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Prophylaxis Maintains High FIX Trough Levels in Hemophilia B

Publish date:: April 3, 2019

Key clinical point: The recombinant factor IX product rIX‐FP (albutrepenonacog alfa) can maintain high steady‐state factor IX trough levels in patients with severe hemophilia B.

Major finding: Steady‐state factor IX trough levels were higher than 5% across all doses in 96.2% and 97.9% of adult/adolescent and pediatric patients, respectively.

Study details: A pharmacokinetic study of 90 patients with severe hemophilia B.

Disclosures: The study was funded by CSL Behring. The authors reported financial disclosures related to Bayer, CSL Behring, Kedrion Biopharma, Novo Nordisk, Pfizer, and others.

Citation:

Gill JC et al. Haemophilia. 2019 Mar 13. doi: 10.1111/hae.13735.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Bleeding Disorders

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

Hemochromatosis variants may confer 10-fold higher risk of liver cancer,

Hemophilia, von Willebrand disease do not increase postop complications for ACL reconstruction,

Mouth splints decrease risk of post–dental extraction bleeding in hemophilia,

Low VWF levels or blood group O not linked to intracerebral hemorrhage risk,